UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 21, 2013 (November 15, 2013)
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
001-16633 |
|
84-1460811 |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
3200 Walnut Street, Boulder, Colorado |
|
80301 |
|
(Address of principal executive offices) |
|
(Zip Code) |
303-381-6600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 15, 2013, Kevin Koch, Ph.D., resigned as President and Chief Science Officer of Array, effective November 29, 2013. Dr. Koch resigned to pursue other professional opportunities and his resignation did not arise from any disagreement on any matter relating to the Array’s operations, policies or practices.
A copy of the press release announcing Dr. Koch’s resignation issued by Array on November 21, 2013 is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release announcing resignation of Kevin Koch, Ph.D. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: November 21, 2013 |
Array BioPharma Inc. | |
|
|
| |
|
|
|
|
|
|
By: |
/s/ R. Michael Carruthers |
|
|
|
R. Michael Carruthers |
|
|
|
Chief Financial Officer |